The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy.
Kim D, Lv J, Hladunewich M, Jha V, Hooi LS, Monaghan H, Shan S, Reich HN, Barbour S, Billot L, Zhang H, Perkovic V, Wong MG; TESTING trial steering committee.
Kim D, et al. Among authors: lv j.
Kidney Int Rep. 2024 Apr 3;9(7):2168-2179. doi: 10.1016/j.ekir.2024.03.032. eCollection 2024 Jul.
Kidney Int Rep. 2024.
PMID: 39081761
Free PMC article.